David Baker is Scientific Co-Founder at CHARM. David Baker is the director of the Institute for Protein Design, a Howard Hughes Medical Institute Investigator, the Henrietta and Aubrey Davis Endowed Professor in Biochemistry, and an adjunct professor of genome sciences, bioengineering, chemical engineering, computer science, and physics at the University of Washington.
David Baker has been leading the field of protein design and protein structure prediction for the last 2 decades, for which he received the Breakthrough Prize in 2021. David has published over 330 peer-reviewed scientific papers, including over 20 in Science and Nature.
David has co-founded a number of biotechnology companies, such as SANA Biotechnologies (NASDAQ: SANA), Lyell Immunopharma (NASDAQ: LYEL) and Icosavax (NASDAQ: ICVX).
With the belief that deep learning will revolutionise structure-based drug discovery, just as it did with protein folding, David Baker joined CHARM as scientific co-founder in 2021.